Expanding Optogenetics to Geographic Atrophy - Summary - MDSpire

Expanding Optogenetics to Geographic Atrophy

Jordi Monés, MD, PhD, discusses the rationale for evaluating MCO-010 (sonpiretigene isteparvovec) in GA following encouraging findings in retinitis pigmentosa and Stargardt disease.

  • By

  • Jordi Monés, MD, PhD

  • July 15, 2026

  • 2 min

Share

Objective:

To evaluate the rationale for using MCO-010 (sonpiretigene isteparvovec) in treating geographic atrophy (GA) following positive results in retinitis pigmentosa (RP) and Stargardt disease.

Approach:
  • Presentation Overview: Jordi Monés, MD, PhD, discussed the rationale for evaluating MCO-010 in GA at the American Society of Retina Specialists meeting.
Key Findings:
  • MCO-010 has shown positive results in improving visual acuity in RP and Stargardt disease.
  • The safety profile of MCO-010 is favorable in both RP and Stargardt patients.
  • The new model of GA indicates potential for MCO-010 to improve vision in advanced cases.
Interpretation:

Clinical trials for GA using MCO-010 are anticipated to begin soon, with expectations of improving vision in patients.

Conclusion:

The use of optogenetics with MCO-010 in GA patients is promising based on previous successes in other retinal diseases.

Original Source(s)

Expanding Optogenetics to Geographic Atrophy

  • by Jordi Monés, MD, PhD

  • July 15, 2026

Related Content

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.

Efficacy of intradermal acupuncture for ocular surface diseases secondary to refractory peripheral facial palsy: a randomized controlled trial study protocol

Ocular Toxoplasmosis Review

Sleep, stress, and pregnancy emerge as potential drivers of ocular toxoplasmosis recurrence in recent retrospective study

  • July 15, 2026

  • 4 min